CARMAT Announces an Agreement with Edwards Lifesciences to Use the Carpentier-Edwards Biological Heart Valves in CARMAT’s Artificial Heart

Regulatory News:

CARMAT (Paris:ALCAR), the designer and developer of the world's most advanced artificial heart, today announced that it has signed an agreement with Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. According to this agreement, CARMAT will be using the Carpentier-Edwards’ biological heart valves in its artificial heart.

Carpentier-Edwards biological heart valves were developed by CARMAT co-founder and CSO Professor Alain Carpentier and will be, for the very first time, used in an artificial heart.

"This partnership with Edwards Lifesciences will enable us to secure a major milestone of our total artificial heart with a view to providing a solution for patients suffering from end-stage heart failure," emphasized CARMAT CEO Marcello Conviti.

The Carpentier-Edwards biological heart valves with proven design, technology, efficacy, and reliability (recognized in the medical world) are essential components of CARMAT’s artificial heart.

This agreement matches CARMAT’s philosophy and very high standards of its artificial heart.

About CARMAT: CARMAT, the world’s most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.
The result of the combination of two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.
Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.
A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.
Substantial involvement of prestigious founders and shareholders: Truffle Capital, the leading European venture capital firm, EADS, the Foundation Alain Carpentier (Carmat’s co-founder) and thousands of institutional and individual shareholders who have also shown their confidence in CARMAT.

For more information: www.carmatsas.com

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR